Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber H H
Department of Neurology, University of Ulm, Germany.
Neuroradiology. 1995 Feb;37(2):113-9.
Serial gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) was used to monitor the effect of mitoxantrone in ten patients with rapidly deteriorating multiple sclerosis (MS). MRI was performed as a baseline and thereafter at 1, 3, 6, 9, 12 and 24 months. The total number of Gd-enhancing lesions diminished from 169 at baseline to 10 after 1 year and to 5 after 2 years. This reduction and the percentage of follow-up MRI studies showing no Gd enhancement were more pronounced than in other MRI studies of the natural course of MS. Measured with quantitative neurological scales, only one patient showed deterioration after 2 years; nevertheless, the changes in MRI were much more marked than those observed clinically. Serial Gd-MRI therefore, seems necessary for documenting efficacy in future therapeutic trials.
采用连续钆（Gd）增强磁共振成像（MRI）来监测米托蒽醌对10例病情迅速恶化的多发性硬化症（MS）患者的疗效。MRI作为基线检查，此后在1、3、6、9、12和24个月时进行检查。钆增强病灶总数从基线时的169个在1年后减少到10个，在2年后减少到5个。这种减少以及随访MRI研究中显示无钆增强的百分比比其他关于MS自然病程的MRI研究更为显著。用定量神经学量表测量，2年后只有1例患者病情恶化；然而，MRI的变化比临床观察到的变化更为明显。因此，连续钆增强MRI似乎对于记录未来治疗试验中的疗效是必要的。
